A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.

Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

Clinicians should not neglect proteinuria testing in adults younger than age 40 years to identify those at high risk for sudden cardiac arrest.

In the CONVERT trial 830 maintenance renal allograft recipients (6–120 months post-transplant ... 20–40 ml/min and in patients with baseline proteinuria. Worsening proteinuria among patients ...